Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats.

@article{Fujishiro2006ChangeFC,
  title={Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats.},
  author={Jun Fujishiro and Chihiro Suzuki and Shinji Kudou and Tokutaro Yasue and Yoji Hakamata and Masafumi Takahashi and Takashi Murakami and Kohei Hashizume and Eiji Otsu-shi Kobayashi},
  journal={The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation},
  year={2006},
  volume={25 7},
  pages={
          825-33
        }
}
BACKGROUND Replacement of calcineurin inhibitor (CI) with anti-metabolic agents in transplant patients with CI-induced nephrotoxicity is performed clinically and improves renal function, but increases the risk of rejection. We investigated whether the change from cyclosporine (CsA) to a limited dose of mycophenolic acid (MPA) together with a new sphingosine-1-phosphate (S1P) receptor agonist, KRP-203, is sufficient to prevent both transplant vasculopathy and CsA-induced nephrotoxicity… CONTINUE READING